Mitochondrial alterations during carcinogenesis. A review of metabolic transformation and targets for anticancer treatments

Advances in Cancer Research

Volumn 119, Issue , 2013, Pages 127-160

  Wang, Xiao ^a   Peralta, Susana ^a   Moraes, Carlos T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

HIF1; Hypoxia; Microenvironment; Mitochondria; MtDNA; Respiration; ROS; Warburg

Indexed keywords

ANTINEOPLASTIC AGENT; BEZAFIBRATE; CAVEOLIN 1; DICHLOROACETIC ACID; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LONIDAMINE; MYC PROTEIN; PROTEIN P53; RAS PROTEIN; SUCCINATE DEHYDROGENASE; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL ENERGY; CELL METABOLISM; CELL SURVIVAL; ENERGY METABOLISM; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; MITOCHONDRIAL RESPIRATION; MITOPHAGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

EID: 84880404541     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407190-2.00004-6     Document Type: Chapter

References (156)

1. Agani F.H., Pichiule P., Chavez J.C., LaManna J.C. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. Journal of Biological Chemistry 2000, 275:35863-35867.
2. Ameln A.K., Muschter A., Mamlouk S., Kalucka J., Prade I., Franke K., et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFbeta. Cancer Research 2011, 71:3306-3316.
3. Andersen S., Donnem T., Stenvold H., Al-Saad S., Al-Shibli K., Busund L.T., et al. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One 2011, 6:e23847.
4. Asterholm I.W., Mundy D.I., Weng J., Anderson R.G., Scherer P.E. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metabolism 2012, 15:171-185.
5. Bader H.L., Hsu T. Systemic VHL gene functions and the VHL disease. FEBS Letters 2012, 586:1562-1569.
6. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
7. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
8. Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Research 2010, 70:2465-2475.
9. Bertram J.S. The molecular biology of cancer. Molecular Aspects of Medicine 2000, 21:167-223.
10. Bonanni B., Puntoni M., Cazzaniga M., Pruneri G., Serrano D., Guerrieri-Gonzaga A., et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. Journal of Clinical Oncology 2012, 30:2593-2600.
11. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
12. Buzzai M., Jones R.G., Amaravadi R.K., Lum J.J., DeBerardinis R.J., Zhao F., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research 2007, 67:6745-6752.
13. Carver L.A., Schnitzer J.E. Caveolae: mining little caves for new cancer targets. Nature Reviews. Cancer 2003, 3:571-581.
14. Cattley R.C. Peroxisome proliferators and receptor-mediated hepatic carcinogenesis. Toxicologic Pathology 2004, 32(Suppl. 2):6-11.
15. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
16. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:11715-11720.
17. Chandel N.S., McClintock D.S., Feliciano C.E., Wood T.M., Melendez J.A., Rodriguez A.M., et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia - A mechanism of 0-2 sensing. Journal of Biological Chemistry 2000, 275:25130-25138.
18. Chen W.L., Kuo K.T., Chou T.Y., Chen C.L., Wang C.H., Wei Y.H., et al. The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis. BMC Cancer 2012, 12:273.
19. Chiche J., Brahimi-Horn M.C., Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. Journal of Cellular and Molecular Medicine 2010, 14:771-794.
20. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
21. Chua Y.L., Dufour E., Dassa E.P., Rustin P., Jacobs H.T., Taylor C.T., et al. Stabilization of Hypoxia-inducible Factor-1α Protein in Hypoxia Occurs Independently of Mitochondrial Reactive Oxygen Species Production. Journal of Biological Chemistry 2010, 285:31277-31284.
22. Cotterman R., Jin V.X., Krig S.R., Lemen J.M., Wey A., Farnham P.J., et al. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Research 2008, 68:9654-9662.
23. Cuezva J.M., Ortega A.D., Willers I., Sanchez-Cenizo L., Aldea M., Sanchez-Arago M. The tumor suppressor function of mitochondria: translation into the clinics. Biochimica et Biophysica Acta 2009, 1792:1145-1158.
24. Dang C.V. c-myc target genes involved in cell growth, apoptosis, and metabolism. Molecular and Cellular Biology 1999, 19:1-11.
25. Dang C.V., Li F., Lee L.A. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability?. Cell Cycle 2005, 4:1465-1466.
26. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 2008, 7:11-20.
27. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 2008, 7:11-20.
28. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:19345-19350.
29. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G.H., et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10:51-64.
30. DeHaan C., Habibi-Nazhad B., Yan E., Salloum N., Parliament M., Allalunis-Turner J. Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells. Molecular Cancer 2004, 3:19.
31. Dekker P.B.D., Hogendoorn P.C.W., Kuipers-Dijkshoorn N., Prins F.A., van Duinen S.G., Taschner P.E.M., et al. SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology. The Journal of Pathology 2003, 201:480-486.
32. Del Galdo F., Sotgia F., de Almeida C.J., Jasmin J.F., Musick M., Lisanti M.P., et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis and Rheumatism 2008, 58:2854-2865.
33. Demaria M., Giorgi C., Lebiedzinska M., Esposito G., D'Angeli L., Bartoli A., et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging 2010, 2:823-842.
34. Deng X., Gao F., Flagg T., Anderson J., May W.S. Bcl2's flexible loop domain regulates p53 binding and survival. Molecular and Cellular Biology 2006, 26:4421-4434.
35. Desagher S., Martinou J.C. Mitochondria as the central control point of apoptosis. Trends in Cell Biology 2000, 10:369-377.
36. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews. Cancer 2003, 3:11-22.
37. Dwarakanath B.S., Singh D., Banerji A.K., Sarin R., Venkataramana N.K., Jalali R., et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. Journal of Cancer Research and Therapeutics 2009, 5(Suppl. 1):S21-S26.
38. Ebert B.L., Gleadle J.M., O'Rourke J.F., Bartlett S.M., Poulton J., Ratcliffe P.J. Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: similarities with the regulation of erythropoietin. Biochemical Journal 1996, 313(Pt 3):809-814.
39. Enomoto N., Koshikawa N., Gassmann M., Hayashi J.I., Takenaga K. Hypoxic induction of hypoxia-inducible factor-1α and oxygen-regulated gene expression in mitochondrial DNA-depleted HeLa cells. Biochemical and Biophysical Research Communications 2002, 297:346-352.
40. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434.
41. Flaig T.W., Gustafson D.L., Su L.J., Zirrolli J.A., Crighton F., Harrison G.S., et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs 2007, 25:139-146.
42. Formentini L., Sanchez-Arago M., Sanchez-Cenizo L., Cuezva J.M. The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. Molecular Cell 2012, 45:731-742.
43. Gaglio D., Metallo C.M., Gameiro P.A., Hiller K., Danna L.S., Balestrieri C., et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Molecular Systems Biology 2011, 7:523.
44. Ganapathy-Kanniappan S., Vali M., Kunjithapatham R., Buijs M., Syed L.H., Rao P.P., et al. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Current Pharmaceutical Biotechnology 2010, 11:510-517.
45. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
46. Gargini R., Garcia-Escudero V., Izquierdo M. Therapy mediated by mitophagy abrogates tumor progression. Autophagy 2011, 7:466-476.
47. Gasparre G., Porcelli A.M., Bonora E., Pennisi L.F., Toller M., Iommarini L., et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:9001-9006.
48. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nature Reviews. Drug Discovery 2003, 2:803-811.
49. Gimenez-Roqueplo A.P., Favier J., Rustin P., Mourad J.J., Plouin P.F., Corvol P., et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. American Journal of Human Genetics 2001, 69:1186-1197.
50. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends in Cell Biology 2008, 18:165-173.
51. Gottlieb E., Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nature Reviews. Cancer 2005, 5:857-866.
52. Graham C.H., Forsdike J., Fitzgerald C.J., Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. International Journal of Cancer 1999, 80:617-623.
53. Guo J.Y., Chen H.Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes & Development 2011, 25:460-470.
54. Guppy M., Greiner E., Brand K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. European Journal of Biochemistry 1993, 212:95-99.
55. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
56. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
57. Heiden M.G.V., Cantley L.C., Thompson C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 2009, 324:1029-1033.
58. Hempel N., Ye H., Abessi B., Mian B., Melendez J.A. Altered redox status accompanies progression to metastatic human bladder cancer. Free Radical Biology & Medicine 2009, 46:42-50.
59. Herrmann P.C., Gillespie J.W., Charboneau L., Bichsel V.E., Paweletz C.P., Calvert V.S., et al. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 2003, 3:1801-1810.
60. Hockel M., Schlenger K., Hockel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Research 1999, 59:4525-4528.
61. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 2001, 93:266-276.
62. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:7455-7460.
63. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:7987-7992.
64. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:7987-7992.
65. Hung W.Y., Huang K.H., Wu C.W., Chi C.W., Kao H.L., Li A.F., et al. Mitochondrial dysfunction promotes cell migration via reactive oxygen species-enhanced β5-integrin expression in human gastric cancer SC-M1 cells. Biochimica et Biophysica Acta 2012, 1820:1102-1110.
66. Imanishi H., Hattori K., Wada R., Ishikawa K., Fukuda S., Takenaga K., et al. Mitochondrial DNA mutations regulate metastasis of human breast cancer cells. PLoS One 2011, 6:e23401.
67. Ishikawa K., Hashizume O., Koshikawa N., Fukuda S., Nakada K., Takenaga K., et al. Enhanced glycolysis induced by mtDNA mutations does not regulate metastasis. FEBS Letters 2008, 582:3525-3530.
68. Ishikawa K., Takenaga K., Akimoto M., Koshikawa N., Yamaguchi A., Imanishi H., et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320:661-664.
69. 2 sensing. Science 2001, 292:464-468.
70. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
71. Jang A., Hill R.P. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clinical & Experimental Metastasis 1997, 15:469-483.
72. Johnson R.F., Witzel I.I., Perkins N.D. p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-κB. Cancer Research 2011, 71:5588-5597.
73. Jokilehto T., Jaakkola P.M. The role of HIF prolyl hydroxylases in tumour growth. Journal of Cellular and Molecular Medicine 2010, 14:758-770.
74. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes & Development 2009, 23:537-548.
75. Jung H.J., Shim J.S., Lee J., Song Y.M., Park K.C., Choi S.H., et al. Terpestacin Inhibits Tumor Angiogenesis by Targeting UQCRB of Mitochondrial Complex III and Suppressing Hypoxia-induced Reactive Oxygen Species Production and Cellular Oxygen Sensing. Journal of Biological Chemistry 2010, 285:11584-11595.
76. Kargiotis O., Chetty C., Gondi C.S., Tsung A.J., Dinh D.H., Gujrati M., et al. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 2008, 27:4830-4840.
77. KC S., Carcamo J.M., Golde D.W. Antioxidants prevent oxidative DNA damage and cellular transformation elicited by the over-expression of c-MYC. Mutation Research 2006, 593:64-79.
78. Kilbride S.M., Prehn J.H. Central roles of apoptotic proteins in mitochondrial function Oncogene, advance online publication. doi:10.1038/onc.2012.348.
79. Kim E.H., Choi K.S. A critical role of superoxide anion in selenite-induced mitophagic cell death. Autophagy 2008, 4:76-78.
80. Kim J.H., Kim H.Y., Lee Y.K., Yoon Y.S., Xu W.G., Yoon J.K., et al. Involvement of mitophagy in oncogenic K-Ras-induced transformation Overcoming a cellular energy deficit from glucose deficiency. Autophagy 2011, 7:1187-1198.
81. Kim J.W., Gao P., Liu Y.C., Semenza G.L., Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Molecular and Cellular Biology 2007, 27:7381-7393.
82. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 2006, 3:177-185.
83. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 2006, 3:177-185.
84. Ko Y.H., Pedersen P.L., Geschwind J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Letters 2001, 173:83-91.
85. Koshikawa N., Hayashi J., Nakagawara A., Takenaga K. Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1α gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. Journal of Biological Chemistry 2009, 284:33185-33194.
86. Lee H.M., Greeley G.H., Englander E.W. Sustained hypoxia modulates mitochondrial DNA content in the neonatal rat brain. Free Radical Biology & Medicine 2008, 44:807-814.
87. Lee S.Y., Jeon H.M., Ju M.K., Kim C.H., Yoon G., Han S.I., et al. Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Research 2012, 72:3607-3617.
88. Li F., Wang Y., Zeller K.I., Potter J.J., Wonsey D.R., O'Donnell K.A., et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Molecular and Cellular Biology 2005, 25:6225-6234.
89. Lisanti M.P., Martinez-Outschoorn U.E., Pavlides S., Whitaker-Menezes D., Pestell R.G., Howell A., et al. Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. Cell Cycle 2011, 10:2059-2063.
90. Lu H., Forbes R.A., Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. Journal of Biological Chemistry 2002, 277:23111-23115.
91. Luo W.B., Hu H.X., Chang R., Zhong J., Knabel M., O'Meally R., et al. Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1. Cell 2011, 145:732-744.
92. Martinez-Outschoorn U.E., Balliet R.M., Rivadeneira D.B., Chiavarina B., Pavlides S., Wang C., et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010, 9:3256-3276.
93. Martinez-Outschoorn U.E., Pestell R.G., Howell A., Tykocinski M.L., Nagajyothi F., Machado F.S., et al. Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle 2011, 10:4208-4216.
94. Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Power surge: supporting cells "fuel" cancer cell mitochondria. Cell Metabolism 2012, 15:4-5.
95. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., et al. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
96. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
97. Mayr J.A., Meierhofer D., Zimmermann F., Feichtinger R., Kogler C., Ratschek M., et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clinical Cancer Research 2008, 14:2270-2275.
98. Mazurek S., Boschek C.B., Hugo F., Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Seminars in Cancer Biology 2005, 15:300-308.
99. Mizushima N. Autophagy: process and function. Genes & Development 2007, 21:2861-2873.
100. Moll U.M., Schramm L.M. p53-an acrobat in tumorigenesis. Critical Reviews in Oral Biology and Medicine 1998, 9:23-37.
101. Mulligan H.D., Tisdale M.J. Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. British Journal of Cancer 1991, 64:1035-1038.
102. Narita M., Shimizu S., Ito T., Chittenden T., Lutz R.J., Matsuda H., et al. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14681-14686.
103. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine 2011, 17:1498-1503.
104. Niho N., Takahashi M., Kitamura T., Shoji Y., Itoh M., Noda T., et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Research 2003, 63:6090-6095.
105. Onnis B., Rapisarda A., Melillo G. Development of HIF-1 inhibitors for cancer therapy. Journal of Cellular and Molecular Medicine 2009, 13:2780-2786.
106. Oudard S., Carpentier A., Banu E., Fauchon F., Celerier D., Poupon M.F., et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. Journal of Neuro-Oncology 2003, 63:81-86.
107. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal 2000, 348:607-614. Pt. 3.
108. Owens K.M., Kulawiec M., Desouki M.M., Vanniarajan A., Singh K.K. Impaired OXPHOS Complex III in Breast Cancer. PLoS One 2011, 6:e23846.
109. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism 2006, 3:187-197.
110. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism 2006, 3:187-197.
111. Pavlides S., Tsirigos A., Migneco G., Whitaker-Menezes D., Chiavarina B., Flomenberg N., et al. The autophagic tumor stroma model of cancer Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010, 9:3485-3505.
112. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
113. Pollard P.J., Briere J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Human Molecular Genetics 2005, 14:2231-2239.
114. Porporato P.E., Dhup S., Dadhich R.K., Copetti T., Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Frontiers in Pharmacology 2011, 2:49.
115. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829-839.
116. Robey I.F., Baggett B.K., Kirkpatrick N.D., Roe D.J., Dosescu J., Sloane B.F., et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Research 2009, 69:2260-2268.
117. Sahin E., Colla S., Liesa M., Moslehi J., Muller F.L., Guo M., et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470:359-365.
118. Sanchez-Cenizo L., Formentini L., Aldea M., Ortega A.D., Garcia-Huerta P., Sanchez-Arago M., et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. Journal of Biological Chemistry 2010, 285:25308-25313.
119. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
120. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concordet J.P., Maire P., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Journal of Biological Chemistry 1996, 271:32529-32537.
121. Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of Biological Chemistry 1994, 269:23757-23763.
122. Sen N., Satija Y.K., Das S. PGC-1α, a Key Modulator of p53, Promotes Cell Survival upon Metabolic Stress. Molecular Cell 2011, 44:621-634.
123. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine 1999, 5:662-668.
124. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6658-6663.
125. Shimizu S., Narita M., Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999, 399:483-487.
126. Simonnet H., Demont J., Pfeiffer K., Guenaneche L., Bouvier R., Brandt U., et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 2003, 24:1461-1466.
127. Sotgia F., Martinez-Outschoorn U.E., Howell A., Pestell R.G., Pavlides S., Lisanti M.P. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annual Review of Pathology 2012, 7:423-467.
128. Sotgia F., Martinez-Outschoorn U.E., Pavlides S., Howell A., Pestell R.G., Lisanti M.P. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research 2011, 13:213.
129. Sotgia F., Whitaker-Menezes D., Martinez-Outschoorn U.E., Flomenberg N., Birbe R.C., Witkiewicz A.K., et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. Cell Cycle 2012, 11:1445-1454.
130. Sotgia F., Williams T.M., Schubert W., Medina F., Minetti C., Pestell R.G., et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. American Journal of Pathology 2006, 168:292-309.
131. Stein M., Lin H., Jeyamohan C., Dvorzhinski D., Gounder M., Bray K., et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 2010, 70:1388-1394.
132. Sun Y., Vashisht A.A., Tchieu J., Wohlschlegel J.A., Dreier L. VDACs recruit Parkin to defective mitochondria to promote mitochondrial autophagy. Journal of Biological Chemistry 2012, 287:40652-40660.
133. Supuran C.T. Development of small molecule carbonic anhydrase IX inhibitors. BJU International 2008, 101(Suppl. 4):39-40.
134. Taddei M.L., Giannoni E., Raugei G., Scacco S., Sardanelli A.M., Papa S., et al. Mitochondrial Oxidative Stress due to Complex I Dysfunction Promotes Fibroblast Activation and Melanoma Cell Invasiveness. Journal of Signal Transduction 2012, 2012:684592.
135. Telang S., Lane A.N., Nelson K.K., Arumugam S., Chesney J. The oncoprotein H-RasV12 increases mitochondrial metabolism. Molecular Cancer 2007, 6:77.
136. Tenenbaum A., Boyko V., Fisman E.Z., Goldenberg I., Adler Y., Feinberg M.S., et al. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?. Cardiovascular Diabetology 2008, 7:18.
137. Tennant D.A., Duran R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nature Reviews. Cancer 2010, 10:267-277.
138. Ter-Pogossian M.M., Phelps M.E., Hoffman E.J., Mullani N.A. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology 1975, 114:89-98.
139. Tong W.H., Sourbier C., Kovtunovych G., Jeong S.Y., Vira M., Ghosh M., et al. The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. Cancer Cell 2011, 20:315-327.
140. Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Molecular Cell 2002, 9:1031-1044.
141. van Waveren C., Sun Y.B., Cheung H.S., Moraes C.T. Oxidative phosphorylation dysfunction modulates expression of extracellular matrix - remodeling genes and invasion. Carcinogenesis 2006, 27:409-418.
142. Vaux D.L., Korsmeyer S.J. Cell death in development. Cell 1999, 96:245-254.
143. Villeneuve C., Guilbeau-Frugier C., Sicard P., Lairez O., Ordener C., Duparc T., et al. p53-PGC-1α Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice. Antioxidants & Redox Signaling 2012, 18:5-18.
144. Walenta S., Wetterling M., Lehrke M., Schwickert G., Sundfor K., Rofstad E.K., et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research 2000, 60:916-921.
145. Wang G.L., Jiang B.H., Rue E.A., Semenza G.L. Hypoxia-Inducible Factor-1 Is a Basic-Helix-Loop-Helix-Pas Heterodimer Regulated by Cellular 0-2 Tension. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:5510-5514.
146. Wang X., Moraes C.T. Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels. Molecular Oncology 2011, 5:399-409.
147. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:4304-4308.
148. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
149. Warburg O., Wind F., Negelein E. The Metabolism of Tumors in the Body. Journal of General Physiology 1927, 8:519-530.
150. Whitehouse S., Randle P.J. Activation of pyruvate dehydrogenase in perfused rat heart by dichloroacetate (Short Communication). Biochemical Journal 1973, 134:651-653.
151. Wolter K.G., Hsu Y.T., Smith C.L., Nechushtan A., Xi X.G., Youle R.J. The Journal of Cell Biology 1997, 139:1281-1292.
152. Yen K.E., Bittinger M.A., Su S.M., Fantin V.R. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010, 29:6409-6417.
153. Yeung S.J., Pan J., Lee M.H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cellular and Molecular Life Sciences 2008, 65:3981-3999.
154. Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nature Reviews. Molecular Cell Biology 2011, 12:9-14.
155. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11:407-420.
156. Zhivotovsky B., Joseph B., Orrenius S. Tumor radiosensitivity and apoptosis. Experimental Cell Research 1999, 248:10-17.